Gene Panel May Predict Lung Cancer Survival
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Gene Panel May Predict Lung Cancer Survival

ANN ARBOR, Mich -- July 21, 2008 -- An analysis involving a panel of genes may be used to predict which lung cancer patients will have the worst survival, according to a study that appears online in Nature Medicine.

The finding could one day lead to a test that would help determine who needs more aggressive treatment.

The researchers looked at 442 lung cancer tissue samples collected from 6 cancer hospitals in North America. They tested the cancer samples to look at the expression of hundreds of genes and factored in clinical predictors such as tumour stage and the patients' gender and age.

The results showed that the lung cancers could be divided into groups with better and worse survival rates.

"We found that looking at clinical data along with gene expression can be a more reliable indicator [to identify which patients need the additional therapy and which patients could potentially avoid it]," said study author David Beer, PhD, University of Michigan Medical School and University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.

"Gene expression is not just a black box approach -- which a lot of researchers think it is. Sometimes knowing the context actually helps you use that information more efficiently."

"Our findings suggest that there is a potential for successfully predicting lung cancer prognosis based on gene expression, but it is likely to be more difficult to develop a clinically useful test than has been suggested by previous studies," said Kerby Shedden, PhD, University of Michigan Medical School.

"It's going to require more assay standardisation and a large prospective study to identify a signature that is ready for clinical use."

The researchers will continue to refine this process, identifying the important genes and testing them on tissue samples. They also plan to test their predictors in a prospective trial, enrolling patients as they are diagnosed and following their progress.

SOURCE: University of Michigan Health System

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities